What is it about?
This review examines how gene polymorphisms influence clinical response and toxicity in patients with diffuse large B cell lymphoma treated with the R‑CHOP regimen. It summarizes pharmacogenomic evidence across genes involved in drug metabolism, immune signaling, and cell cycle control that may explain inter‑individual variability.
Featured Image
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Why is it important?
Despite standardized therapy, patients show heterogeneous outcomes and frequent toxicities. Understanding how combinations of genetic variants affect efficacy and tolerability supports more informed prognostic stratification and highlights the clinical relevance of pharmacogenetics in oncology.
Perspectives
The evidence comes from heterogeneous studies and focuses on associations rather than clinical implementation. The review emphasizes that single polymorphisms have limited predictive value and that future progress requires integrated analyses of multiple variants within the full therapeutic protocol.
Prof. Antonio Speciale
University of Messina
Read the Original
This page is a summary of: How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma, Blood Reviews, July 2017, Elsevier,
DOI: 10.1016/j.blre.2017.02.005.
You can read the full text:
Contributors
The following have contributed to this page
